Abstract:G protein-coupled dopamine receptors (D1, D2, D3, D4, and D5) mediate all of the physiological functions of the catecholaminergic neurotransmitter dopamine, ranging from voluntary movement and reward to hormonal regulation and hypertension. Pharmacological agents targeting dopaminergic neurotransmission have been clinically used in the management of several neurological and psychiatric disorders, including Parkinson's disease, schizophrenia, bipolar disorder, Huntington's disease, attention deficit hyperactivity disorder (ADHD(1)), and Tourette's syndrome. Numerous advances have occurred in understanding the general structural, biochemical, and functional properties of dopamine receptors that have led to the development of multiple pharmacologically active compounds that directly target dopamine receptors, such as antiparkinson drugs and antipsychotics. Recent progress in understanding the complex biology of dopamine receptor-related signal transduction mechanisms has revealed that, in addition to their primary action on cAMP-mediated signaling, dopamine receptors can act through diverse signaling mechanisms that involve alternative G protein coupling or through G protein-independent mechanisms via interactions with ion channels or proteins that are characteristically implicated in receptor desensitization, such as β-arrestins. One of the future directions in managing dopamine-related pathologic conditions may involve a transition from the approaches that directly affect receptor function to a precise targeting of postreceptor intracellular signaling modalities either directly or through ligand-biased signaling pharmacology. In this comprehensive review, we discuss dopamine receptor classification, their basic structural and genetic organization, their distribution and functions in the brain and the periphery, and their regulation and signal transduction mechanisms. In addition, we discuss the abnormalities of dopamine receptor expression, function, and signaling that are documented in human disorders and the current pharmacology and emerging trends in the development of novel therapeutic agents that act at dopamine receptors and/or on related signaling events.

Structural genomics of the human dopamine receptor system

Dopaminergic Pharmacology Revealed by Structures of Human Dopamine D3 Receptor-G I Complexes

Structures of the human dopamine D3 receptor-Gi complexes

Structural insights into the human D1 and D2 dopamine receptor signaling complexes

Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist

Recent Advances Towards the Discovery of Dopamine Receptor Ligands

Ligand recognition and allosteric regulation of DRD1-Gs signaling complexes

Ligand recognition and biased agonism of the D1 dopamine receptor

Structural insights into G protein activation by D1 dopamine receptor

Structure-based drug design for dopamine D3 receptor.

Computational modeling toward understanding agonist binding on dopamine 3.

Molecular Modeling of the Three-Dimensional Structure of Dopamine 3 (D3) Subtype Receptor: Discovery of Novel and Potent D3 Ligands Through a Hybrid Pharmacophore- and Structure-Based Database Searching Approach.

The Physiology, Signaling, and Pharmacology of Dopamine Receptors

Homology modeling of Dopamine D2 receptor

Structural insight into the serotonin (5-HT) receptor family by molecular docking, molecular dynamics simulation and systems pharmacology analysis

A Computational Perspective on Drug Discovery and Signal Transduction Mechanism of Dopamine and Serotonin Receptors in the Treatment of Schizophrenia

Structural Basis for Molecular Recognition at Serotonin Receptors

Selectivity and Activation of Dopamine D3R from Molecular Dynamics

Dopamine reuptake and inhibitory mechanisms in human dopamine transporter

Computational insights into diverse binding modes of the allosteric modulator and their regulation on dopamine D1 receptor

Computational study on new natural compound agonists of dopamine receptor